LinusBio will develop a technology platform that builds on breakthroughs in exposome sequencing by environmental medicine and public health specialists Drs. Manish Arora, Christine Austin, and Paul Curtin, co-founders of the company. The trio developed a method for sequencing the exposome and biological responses at a molecular level using an environmental biodynamics platform.

The spinoff's pipeline includes precision exposome medicine biomarkers across disease domains for which historically no molecular endpoints have been available in clinical trials, including autism spectrum disorder, amyotrophic lateral sclerosis, inflammatory bowel disease, renal disease, and oncology, the company said. These are diseases for which genomic sequencing alone cannot sufficiently characterize underlying biological disease pathways.

Subject to regulatory approvals, LinusBio intends to launch its first product, StrandDx-ASD, a molecular biomarker for autism spectrum disorder that can be applied at birth, LinusBio said.